ACW Clinical Trials Science Forum 2023: Alzheimer’s: amyloid therapies are only part of the answer

Actinogen Medical (ASX : ACW) held its Clinical Trials Science Forum via webcast on 24 May.
‘Following the Science’ is fundamental to all Actinogen’s activities. This plain english presentation is designed to explain the science behind targeting amyloid in Alzheimer’s disease and the opportunity for non-amyloid treatments such as Xanamem.
Hear from ACW executive team members as they explore the following topics:
1. An overview of the current ‘state of play’ on clinical AD research (CEO, Dr Steven Gourlay)
2. An introduction to the Xanamem drug product and in particular its tablet formulation by Dr Fujun Li, Head of Manufacturing, that has been developed for the upcoming XanaMIA Phase 2b AD trial and all subsequent trials
3. An insightful high-level analysis from ACW CMO and neurologist, Dr Dana Hilt on the role of treating AD with anti-amyloid antibody therapy and the significant opportunity remaining for alternative and complementary approaches